Munich, Germany, 14 September 2016 - Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that people treated with Saxenda ® (liraglutide 3 mg) experienced consistent weight loss and improved blood glucose control across baseline body mass index (BMI) categories over three years as compared to placebo treatment. These data were presented today at the 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.
|Katrine Sperling||+45 4442 email@example.com|
|Åsa Josefsson||+45 3079 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Melanie Raouzeos||+45 3075 firstname.lastname@example.org|
|Hanna Ögren||+45 3079 email@example.com|
|Kasper Veje (US)||+1 609 235 firstname.lastname@example.org|
Last updated on: 15/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.